Status:
UNKNOWN
Next-generation Sequencing in Gastrointestinal Cancer
Lead Sponsor:
Fujian Cancer Hospital
Conditions:
Gastrointestinal Cancer
Eligibility:
All Genders
Brief Summary
Liquid biopsy has been successfully applied to the treatment and diagnosis of cancer. cfDNA has been paid more and more attention in liquid biopsy. Previous studies have shown that cfDNA can be used f...
Detailed Description
Sample DNA handling： Peripheral blood lymphocytes (PBLs), and plasma were collected for analysis for each patient. 10mL tubes containing blood samples with EDTA added were centrifuged at 1000g for 10m...
Eligibility Criteria
Inclusion
- patients with pathologically confirmed Stage III/ IV gastrointestinal cancer
- all patients had not received chemotherapy
Exclusion
- \-
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03476057
Start Date
July 1 2018
End Date
December 31 2020
Last Update
July 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rongbo Lin
Fuzhou, Fujian, China, 350014